Document |
Document Title |
WO/2008/117796A1 |
The invention relates to mutilin derivatives represented by the general formula (I) which are useful as antimicrobial agent against multidrug-resistant bacteria; and intermediates for the production of the same. In the general formula (I...
|
WO/2008/116302A1 |
The present invention relates to novel compounds of the formula (I), wherein R'-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of ca...
|
WO/2008/096001A1 |
Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof;usefulas HCV inhibitors; processes for preparing these c...
|
WO/2008/038964A1 |
Disclosed are geldanamycin derivatives of Chemical Formula 1, pharmaceutically acceptable salts thereof, a preparation method thereof, and agents for the preparation and treatment of cancerous diseases, comprising the same as an active i...
|
WO/2008/021956A2 |
The present invention discloses compounds of formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A ...
|
WO2006136564A9 |
Compounds of general formula (I): in which: R1, R2, R3, R4, R5 and FG are as defined in the specification and claims, optionally conjugated with a suitable molecule able to interact with physiological systems; and their chelates with bi-...
|
WO/2008/009734A1 |
The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicament...
|
WO/2008/009750A2 |
The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments...
|
WO/2008/002924A2 |
The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV)...
|
WO/2007/149543A2 |
A method for treating a scar comprises administering to a scar a pharmaceutically effective amount of one or more blistering agents in a pharmaceutically acceptable carrier.
|
WO/2007/117180A1 |
The invention relates to novel azaheterocycles of interest as potential physiologically active substances (agonists, antagonists, receptor modulators, ferment inhibitors, oncolytics, antibacterial and antiparasitic agent etc.), to combin...
|
WO/2007/077004A1 |
The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicament...
|
WO/2007/076431A1 |
The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, a...
|
WO/2007/055700A1 |
Lanthanide chelates derived from diazacrown ethers having two ethyliminodiacetic acid side chains have increased ability to bind lanthanide ions.
|
WO/2007/047737A1 |
Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or con...
|
WO/2007/014926A1 |
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR7, -NH-SO2R8; R2 is hydrog...
|
WO/2007/014922A1 |
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 i...
|
WO/2007/014925A1 |
Inhibitors of HCV replication of formula (I), and the N-oxides, salts, and stereoisomers thereof, wherein each dashed line represents an optional double bond; X is Ν, CH and where X bears a double bond it is C; R1a and R1b are hydrogen,...
|
WO/2006/137769A1 |
There is provided processes for the preparation of various compounds, including compounds of formulae I, IV and VII, [Chemical formulas should be inserted here. Please see paper copy] or salts and/or solvates thereof, which compounds are...
|
WO/2006/103009A1 |
The invention concerns antibacterial amide macrocycles , methods for producing same, their use for treating and/or preventing diseases, as well as their use for producing drugs for treating and/or preventing diseases, in particular bacte...
|
WO/2006/095795A1 |
A cyclic dinitron compound is produced by stirring a cyclic nitron compound-containing solution in the presence of an acid catalyst to selectively conduct a ring enlarging dimerization reaction. The cyclic nitron compound is more prefera...
|
WO/2006/074940A2 |
The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 o...
|
WO/2005/118613A2 |
The invention relates to antibacterial amide macrocycles and to methods for producing them, to their use in the treatment and/or prophylaxis of diseases and to their use for producing drugs for use in the treatment and/or prophylaxis of ...
|
WO/2005/117876A1 |
The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods ...
|
WO/2005/077908A1 |
A guanidine compound which has a bi-aryl skeleton represented by the following general formula (1): [wherein R1, R2 and R3 each independently represents a hydrogen atom, a hydrocarbon group optionally having a substituent or a heterocycl...
|
WO/2005/077921A1 |
A guanidine compound which has a bi-aryl skeleton represented by the following general formula (1): [wherein R1, R2 and R3 each independently represents a hydrogen atom, a hydrocarbon group optionally having a substituent or a heterocycl...
|
WO/2005/074598A2 |
Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions.
|
WO/2005/073216A2 |
Compounds of the formula (F) where the variables are as defined in the specification inhibit the NS3 protease of flavivirus sych as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those ...
|
WO/2005/073195A2 |
Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocycli...
|
WO/2005/061467A2 |
Compounds (I) are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical comp...
|
WO/2005/049585A1 |
The present invention relates to novel macrocyclic compounds of the formula (I) wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or...
|
WO/2005/030796A1 |
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. T...
|
WO/2005/017124A2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
WO/2004/099162A1 |
Compounds of Formula 8 are provided: A and B are each independently selected from the group consisting of -NO-, -SO-, and - NR9-. C is a single bond or a double bond. D is selected from the group consisting of single bond, E is selected ...
|
WO/2004/089300A2 |
The present invention relates to compounds of Formula (I): their pharmaceutical composition and their utility in treating neoplasm.
|
WO/2004/084809A2 |
Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by ne...
|
WO/2004/007445A2 |
One aspect of the present invention relates to amide-bearing substituted benzolactams, and individual stereoisomers thereof. A second aspect of the present invention relates to combinatorial libraries of the aforementioned amide-bearing ...
|
WO/2003/106480A1 |
The invention relates to antibacterial amide macrocycles, to methods for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of illness, especially bacterial infections.
|
WO/2003/074476A1 |
An arylamidine derivative represented by the general formula (1) (wherein X means optionally substituted lower alkylene or alkenylene; G1 means oxygen, sulfur, or imino; G2 means carbon or nitrogen; Ra means at least one member selected ...
|
WO/2003/008390A1 |
Compounds of general formula (I):in which: R¿1? is hydrogen, C¿1?-C¿2O? alkyl, C¿3?-C¿10? cycloalkyl, C¿4?-C¿2O? cycloalkylalkyl, aryl, arylalkyl, or two R1, taken together, form a straight or cyclic C¿2?-C¿10? alkylene group or...
|
WO/2003/002545A1 |
The invention relates to new peptoid compounds of formula (I), as well as their use in the treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms, and to compositions thereof.
|
WO/2002/088115A1 |
The present invention relates to a novel sulfonamide derivatives and novel intermediates thereof, preparation thereof, and a pharmaceutical composition comprising the same, and more particularly, to novel sulfonamide derivatives and inte...
|
WO/2002/085838A1 |
The present invention relaters to copper-catalyzed carbon-heteroatom and carbon-carbon bond-forming methods. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between the ...
|
WO/2002/028864A1 |
There is provided a process for the preparation of a compound of formula I, (I), or a pharmaceutically acceptable derivative thereof, wherein A, B, G, R?1¿, R?2¿, R?3¿, R?4¿ and R?41¿ to R?46¿ have meanings given in the description...
|
WO/2002/028863A1 |
There is provided 4-({3-[7-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo[3.
3.1]non-3-yl]propyl}amino)benzonitrile, benzenesulfonic acid salt, which compound is useful in the prophylaxis and in the treatment of arrhythmias, in particu...
|
WO/2001/040198A2 |
The invention concerns macrocyclic hydroxamic acid derivatives of general formula (I) wherein: Y is -CH¿2?-, -CH¿2?-CH¿2?- or -CH=CH- and Z and Z' represent -CH¿2?- or Y-Z or Y-Z' represent -CH=CH- and Z and Z' are defined as above; ...
|
WO/2001/016110A1 |
Formulation components such as bleach boosting compounds selected from the group consisting of bleach boosters comprising quaternary imine cations, zwitterions, polyions having a net charge of from about +3 to about -3 and mixtures there...
|
WO/2001/010848A2 |
Compounds of formula (I) in which M is the following central building block (a) are novel effective trypase-inhibitors.
|
WO/2000/069830A1 |
The synthesis of individual di- and tri-substituted-1,4-diazacyclic compounds having 6- to 8-atoms in the cyclic ring, their corresponding 1,6-diketo-2,5-diazacyclic compounds and similar 1,4-diazacyclic ring compounds having one ring ca...
|
WO/2000/058294A1 |
Compounds of formula (I) are antibacterial agents wherein: R¿3? and R¿4?, taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 1...
|